ACC issues concise clinical guidance on evaluation and management of cardiogenic shock
The American College of Cardiology (ACC) has issued its first Concise Clinical Guidance (CCG) to create more streamlined and efficient processes to implement best practices in patient care.
This CCG, which appears in the Journal of the American College of Cardiology, focuses on evaluating and managing cardiogenic shock (CS), addressing important questions around clinical decision-making and providing actionable guidance for health care providers.
A session at the ACC's Annual Scientific Session (ACC.25), taking place March 29–31 in Chicago, will introduce CCGs as a new clinical policy format for the ACC and will formally present this document as the first publication to use the format.
"ACC has a long history of developing clinical policy to complement clinical practice guidelines and to inform clinicians about areas where evidence is new and evolving or where randomized data is more limited. Despite this, numerous gaps persist in the evaluation and management of CS," said Shashank S. Sinha, MD, MSc, FACC, writing committee chair and advanced heart failure and transplant cardiologist at the Inova Fairfax Medical Campus.
"Concise Clinical Guidance represents a key component of solution sets. They are highly focused, limited in scope, and aim to illustrate clinical decision-making processes using figures, tables, and checklists. They address patient populations who share certain characteristics, such as critically ill conditions like CS."
Dr. Sinha serves as Director, Cardiogenic Shock Program, Inova Health System; Medical Director of the Cardiac Intensive Care Unit, Cardiology; and Director of the Cardiovascular Critical Care Research Program.
CS is a life-threatening condition that occurs when the heart is unable to pump enough oxygen-rich blood to the body's organs, resulting in hypotension (low blood pressure) and multi-organ damage or failure. CS has a high in-hospital mortality rate, ranging from 30 to 50%, and is one of the most common causes of cardiac intensive care admission.
The CCG addresses the importance of early recognition of CS for improving patient outcomes, providing comprehensive recommendations for its initial assessment, introducing a new mnemonic, SUSPECT CS, which includes laboratory markers along with clinical assessment for congestion such as pulmonary edema, jugular venous distension and peripheral edema and hypoperfusion.
"These markers should include a complete blood count, comprehensive metabolic panel, cardiac biomarkers including troponin and natriuretic peptides, lactic acid and arterial or venous blood gas," Sinha said.
"Once CS is suspected, a 12-lead electrocardiogram, chest radiography—and a transthoracic echocardiogram and/or point-of-care ultrasound, if available—should be completed as soon as possible."
Other recommendations outlined in the CCG include invasive hemodynamic monitoring via pulmonary artery catheter for both the diagnosis and management of CS.
It provides guidance on the medical management of CS with a focus on maintaining tissue perfusion to preserve organ performance. It also provides guidance on what to do when end-organ perfusion cannot be maintained with pharmacological interventions alone with escalation to temporary mechanical circulatory support.
For the first time, the CCG provides a one-hour and 24-hour roadmap for clinicians on the evaluation and management of CS.
In addition, it provides recommendations for the pharmacological and temporary mechanical circulatory support treatment for CS, highlights the need for ongoing patient monitoring, reassessment and follow-up, and provides guidance for the decision-making around a patient's candidacy for advanced therapies, heart recovery or transfers to advanced heart failure centers.
It also underscores the importance of interdisciplinary, team-based collaboration for the care of patients with CS.
"Community-based centers with limited resources should identify an on-site clinician to serve as their 'shock champion' as well as a center providing advanced heart failure therapies to partner with on complex CS cases," Sinha said. "These partnerships are a key ingredient to successful strategies for managing this complex syndrome."
More information:
2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on the Evaluation and Management of Cardiogenic Shock, Journal of the American College of Cardiology (2025). DOI: 10.1016/j.jacc.2025.02.018
ACC's Solutions Sets: Real-Time Support for the Frontline Cardiovascular Clinician. March 31 at 11:30 a.m. CT / 12:30 p.m. ET.
Provided by American College of Cardiology